Literature DB >> 28849183

FTO expression is associated with the occurrence of gastric cancer and prognosis.

Dong Xu1, Weiwei Shao2, Yasu Jiang3, Xi Wang4, Ying Liu5, Xianchen Liu6.   

Abstract

Fat mass and obesity associated (FTO) is a protein-coding gene. FTO gene is an obesity related gene, also known as the obesity gene. It has been reported previously that FTO is associated with a variety of malignant cancers, such as breast, thyroid and endometrial cancer. The aim of the present study was investigate the FTO expression of human gastric cancer and to investigate its clinical value. FTO expression was determined by immunohistochemical analysis with tissue microarrays in GC tissues and corresponding adjacent non-tumor tissues. Moreover, the results in protein and mRNA level were confirmed by the real-time PCR and western blot analysis. The relationship between the FTO expression and the pathological characteristics of GC patients was also explored. In addition, by using MTT, clone formation and transwell assays, we studied the effects of FTO expression on biological function of GC cells in vitro. The Kaplan-Meier method and the log-rank test were used to compare the overall survival rate between the FTO high-expression group and the low-expression group. We affirmed repeatedly upregulation of FTO expression in both protein and mRNA levels in GC tissues compared to corresponding adjacent non-tumor tissues. Immunohistochemistry by tissue microarray of FTO expression was remarkably increased in GC tissues (72 of 128, 56.3%) compared with adjacent non-tumor tissues (24 of 62, 38.7%). FTO expression level was closely related to low differentiation (P<0.001), lymph node metastasis (P=0.029). The expression of FTO was positively correlated with TNM stage (P<0.001). the Kaplan-Meier analysis showed that high FTO expression was significantly associated with poor prognosis in GC patients. Downregulation of FTO expression significantly inhibited the proliferation, migration and invasion of GC cell lines. On the contrary, overexpression of FTO promoted the proliferation, migration and invasion of GC cell lines. This study indicates that FTO expression may have an important role in promoting the occurrence of GC, and it may be an vital molecular marker in the diagnosis and prognosis of GC patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28849183     DOI: 10.3892/or.2017.5904

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  57 in total

1.  Fusaric acid decreases p53 expression by altering promoter methylation and m6A RNA methylation in human hepatocellular carcinoma (HepG2) cells.

Authors:  Terisha Ghazi; Savania Nagiah; Anil A Chuturgoon
Journal:  Epigenetics       Date:  2020-07-07       Impact factor: 4.528

Review 2.  Novel positioning from obesity to cancer: FTO, an m6A RNA demethylase, regulates tumour progression.

Authors:  JiaLing Chen; Bin Du
Journal:  J Cancer Res Clin Oncol       Date:  2018-11-21       Impact factor: 4.553

Review 3.  N6-methyladenine RNA modification and cancer.

Authors:  Jun Yang; Junwen Chen; Xiang Fei; Xia Wang; Kefeng Wang
Journal:  Oncol Lett       Date:  2020-06-16       Impact factor: 2.967

4.  FTO promotes multiple myeloma progression by posttranscriptional activation of HSF1 in an m6A-YTHDF2-dependent manner.

Authors:  Aoshuang Xu; Jiasi Zhang; Liping Zuo; Han Yan; Lei Chen; Fei Zhao; Fengjuan Fan; Jian Xu; Bo Zhang; Yuyang Zhang; Xuejiao Yin; Qianwen Cheng; Su Gao; Jun Deng; Heng Mei; Zhiping Huang; Chunyan Sun; Yu Hu
Journal:  Mol Ther       Date:  2021-12-13       Impact factor: 11.454

5.  FTO Prevents Thyroid Cancer Progression by SLC7A11 m6A Methylation in a Ferroptosis-Dependent Manner.

Authors:  Fei-Hong Ji; Xing-Hao Fu; Guo-Quan Li; Qi He; Xin-Guang Qiu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-03       Impact factor: 6.055

Review 6.  Progress and application of epitranscriptomic m6A modification in gastric cancer.

Authors:  Yitian Xu; Chen Huang
Journal:  RNA Biol       Date:  2022-01       Impact factor: 4.766

7.  Effect of Posttranslational Modifications on the Structure and Activity of FTO Demethylase.

Authors:  Michał Marcinkowski; Tomaš Pilžys; Damian Garbicz; Jan Piwowarski; Damian Mielecki; Grzegorz Nowaczyk; Michał Taube; Maciej Gielnik; Maciej Kozak; Maria Winiewska-Szajewska; Ewa Szołajska; Janusz Dębski; Agnieszka M Maciejewska; Kaja Przygońska; Karolina Ferenc; Elżbieta Grzesiuk; Jarosław Poznański
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

Review 8.  RNA N6-methyladenosine modification in solid tumors: new therapeutic frontiers.

Authors:  Laleh Melstrom; Jianjun Chen
Journal:  Cancer Gene Ther       Date:  2020-01-20       Impact factor: 5.987

Review 9.  Methylation Landscape: Targeting Writer or Eraser to Discover Anti-Cancer Drug.

Authors:  Wen-Min Zhou; Bin Liu; Amin Shavandi; Lu Li; Hang Song; Jian-Ye Zhang
Journal:  Front Pharmacol       Date:  2021-06-03       Impact factor: 5.810

10.  N6-Methyladenosine RNA Demethylase FTO Promotes Gastric Cancer Metastasis by Down-Regulating the m6A Methylation of ITGB1.

Authors:  Duo Wang; Xiujuan Qu; Wenqing Lu; Yizhe Wang; Yue Jin; Kezuo Hou; Bowen Yang; Ce Li; Jianfei Qi; Jiawen Xiao; Xiaofang Che; Yunpeng Liu
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.